Sino Biopharmaceutical

Diversified pharma

1177 · HKEX · China

Public Market Listing

1177HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Sino Biopharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(16 total)
16Total Assets
1Approved
7Phase 3 / Filed
8Phase 1–2 / Early
11Diseases
Quick filter:
Showing 16 of 16 assets
Target & Modality
Approved
Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule
Chronic Obstructive Pulmonary Disease
Phase 3
CDK2/CDK4/CDK6 · CDK2/4/6/CDK4Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Garsorasib(Anfangning)
Phase 3
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Phase 3
AKT (inhibitor)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
HBV core protein
Chronic Hepatitis B
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 3
PDE3/PDE4Small molecule
Chronic Obstructive Pulmonary Disease
Phase 3
TYK2Small molecule
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisSystemic Lupus Erythematosus
Ulcerative Colitis, Crohn's Disease
Phase 2
Lipoprotein(a)RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 2
TLR8
Chronic Hepatitis B
Phase 2
IL-36 receptor (IL-36R)Monoclonal antibody
Psoriasis
Phase 1/2
—
Chronic Hepatitis B
Phase 1
APOC3RNA / oligonucleotide
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Phase 1
GPRC5D x CD3Multispecific antibody
Multiple Myeloma
TQB3602No recent activity
Phase 1
ProteasomeSmall molecule
Multiple Myeloma

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
CulmerciclibPhase 1/2Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
Est. primary completion 2026-12 · NCT06202261 · CT.gov ↗
What to watch
CulmerciclibPhase 3Breast Cancer
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
2027 (6)
February 2027 (1)
TQC3721Phase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2027-02 · NCT07464587 · CT.gov ↗
What to watch
March 2027 (1)
TQC3721Phase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2027-03 · NCT07147946 · CT.gov ↗
What to watch
August 2027 (1)
TQH3906Phase 2Psoriatic Arthritis
Est. primary completion 2027-08 · NCT07406035 · CT.gov ↗
What to watch
September 2027 (1)
TQH3906Phase 3Psoriasis
Est. primary completion 2027-09 · NCT07724366 · CT.gov ↗
What to watch
November 2027 (1)
TQH3906Phase 2Systemic Lupus Erythematosus
Est. primary completion 2027-11 · NCT07509892 · CT.gov ↗
What to watch
December 2027 (1)
Garsorasib · AnfangningPhase 1/2Solid Tumor
Est. primary completion 2027-12-31 · NCT05379946 · CT.gov ↗
What to watch
2028 (3)
August 2028 (1)
NTQ1062Phase 3HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Est. primary completion 2028-08-31 · NCT07393321 · CT.gov ↗
What to watch
September 2028 (1)
TQA3605Phase 3Chronic Hepatitis B
Est. primary completion 2028-09 · NCT07797231 · CT.gov ↗
What to watch
December 2028 (1)
TQB2934Phase 3Multiple Myeloma
Est. primary completion 2028-12 · NCT07569757 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 May 2026ApprovalCulmerciclibNMPA approves culmerciclib plus fulvestrant first-line
CN, NMPA · Chia Tai Tianqing Pharmaceutical Group · Source ↗

Financial reports

Quarterly & interim (5)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$2.4B$440M$1.5B—report ↗

Sino Biopharmaceutical reported revenue of $2,424.38M, up 9.9% YoY, with R&D spend of $439.83M, up 22.7% YoY. Cash and equivalents were $1,549.61M. Profit attributable to owners of the parent from continuing operations was approximately RMB3.39 billion, up 140.2% YoY, with earnings per share of approximately RMB18.82 cents; underlying profit attributable to owners was approximately RMB3.09 billion, up 101.1% YoY.

During 1H 2025, two innovative products were approved by the NMPA (Putanning and Anqixin), and five generic drugs received approval; innovative product sales reached RMB7.8 billion, up 27.2% YoY. The company reported 37 innovative oncology candidates, 7 liver/metabolic candidates, 13 respiratory candidates, and 6 surgery/analgesia candidates in clinical trial application or above, including multiple Phase III programs such as Lanifibranor for MASH. In July 2025, the company announced the full acquisition of LaNova Medicines, and the board recommended an interim dividend of HK5 cents per share.

View 4 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1$2.2B$358M$1.2B—report ↗
2023-H1$2.2B$340M$1.6B—report ↗
2022-H1$2.3B$317M$1.2B—report ↗
2021-H1$2.2B$275M$1.2B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$4.7B$866M$1.8B—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$4.0B$708M$1.3B—report ↗
2023-FY$3.7B$666M$1.3B—report ↗
2022-FY$4.3B—$1.7B—report ↗
2021-FY$4.2B—$1.7B—report ↗